Patents by Inventor Frederick R. Taylor

Frederick R. Taylor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-VLA-4 ANTIBODIES
    Publication number: 20240100155
    Abstract: This invention relates to alpha-4 binding antibodies, and fragments thereof.
    Type: Application
    Filed: February 6, 2023
    Publication date: March 28, 2024
    Applicant: BIOGEN MA INC.
    Inventors: Alexey A. Lugovskoy, Frederick R. Taylor, Karen McLachlan
  • BINDING PROTEINS, INCLUDING ANTIBODIES, ANTIBODY DERIVATIVES AND ANTIBODY FRAGMENTS, THAT SPECIFICALLY BIND CD154 AND USES THEREOF
    Publication number: 20230135399
    Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD4OL) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.
    Type: Application
    Filed: September 7, 2022
    Publication date: May 4, 2023
    Inventors: LINDA C. BURKLY, JANINE L. FERRANT-ORGETTAS, ELLEN A. GARBER, YEN-MING HSU, LIHE SU, FREDERICK R. TAYLOR, RALPH ADAMS, DEREK THOMAS BROWN, ANDREW GEORGE POPPLEWELL, MARTYN KIM ROBINSON, ANTHONY SHOCK, KERRY LOUISE TYSON
  • Anti-VLA-4 antibodies
    Patent number: 11571477
    Abstract: This invention relates to alpha-4 binding antibodies, and fragments thereof.
    Type: Grant
    Filed: July 2, 2021
    Date of Patent: February 7, 2023
    Assignee: Biogen MA Inc.
    Inventors: Alexey A. Lugovskoy, Frederick R. Taylor, Karen McLachlan
  • ANTI-VLA-4 ANTIBODIES
    Publication number: 20210401981
    Abstract: This invention relates to alpha-4 binding antibodies, and fragments thereof.
    Type: Application
    Filed: July 2, 2021
    Publication date: December 30, 2021
    Applicant: BIOGEN MA INC.
    Inventors: Alexey A. Lugovskoy, Frederick R. Taylor, Karen McLachlan
  • Anti-VLA-4 antibodies
    Patent number: 11083791
    Abstract: This invention relates to alpha-4 binding antibodies, and fragments thereof.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: August 10, 2021
    Assignee: Biogen MA Inc.
    Inventors: Alexey A. Lugovskoy, Frederick R. Taylor, Karen McLachlan
  • ANTI-VLA-4 ANTIBODIES
    Publication number: 20190365892
    Abstract: This invention relates to alpha-4 binding antibodies, and fragments thereof.
    Type: Application
    Filed: June 14, 2019
    Publication date: December 5, 2019
    Applicant: BIOGEN MA INC.
    Inventors: Alexey A. Lugovskoy, Frederick R. Taylor, Karen McLachlan
  • BINDING PROTEINS, INCLUDING ANTIBODIES, ANTIBODY DERIVATIVES AND ANTIBODY FRAGMENTS, THAT SPECIFICALLY BIND CD154 AND USES THEREOF
    Publication number: 20190233530
    Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.
    Type: Application
    Filed: April 10, 2019
    Publication date: August 1, 2019
    Inventors: Linda C. Burkly, Janine L. Ferrant-Orgettas, Ellen A. Garber, Yen-Ming Hsu, Lihe Su, Frederick R. Taylor, Ralph Adams, Derek Thomas Brown, Andrew George Popplewell, Martyn Kim Robinson, Anthony Shock, Kerry Louise Tyson
  • Anti-VLA-4 antibodies
    Patent number: 10335485
    Abstract: This invention relates to alpha-4 binding antibodies, and fragments thereof.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: July 2, 2019
    Assignee: Biogen MA Inc.
    Inventors: Alexey A. Lugovskoy, Frederick R. Taylor, Karen McLachlan
  • ANTI-BLOOD DENDRITIC CELL ANTIGEN 2 ANTIBODIES AND USES THEREOF
    Publication number: 20180362652
    Abstract: Antibodies and antibody fragments that bind to BDCA2 are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to induce death of a plasmacytoid dendritic cell, inhibit production or secretion of inflammatory cytokines and chemokines, and treat or prevent immunological disorders such as inflammatory and autoimmune conditions.
    Type: Application
    Filed: January 12, 2018
    Publication date: December 20, 2018
    Applicant: Biogen MA Inc.
    Inventors: Justin A. Caravella, Ellen A. Garber Stark, Dania Mounir Rabah, Frederick R. Taylor
  • ANTI-VLA-4 ANTIBODIES
    Publication number: 20180221480
    Abstract: This invention relates to alpha-4 binding antibodies, and fragments thereof.
    Type: Application
    Filed: December 12, 2017
    Publication date: August 9, 2018
    Inventors: Alexey A. Lugovskoy, Frederick R. Taylor, Karen McLachlan
  • Anti-blood dendritic cell antigen 2 antibodies and uses thereof
    Patent number: 9902775
    Abstract: Antibodies and antibody fragments that bind to BDCA2 are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to induce death of a plasmacytoid dendritic cell, inhibit production or secretion of inflammatory cytokines and chemokines, and treat or prevent immunological disorders such as inflammatory and autoimmune conditions.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: February 27, 2018
    Assignee: Biogen MA Inc.
    Inventors: Justin A. Caravella, Ellen A. Garber Stark, Dania Mounir Rabah, Frederick R. Taylor
  • Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
    Patent number: 9738707
    Abstract: The present invention features inter alia polypeptides comprising heterodimeric Fc regions. In addition, the instant invention provides methods for treating or preventing a disease or disorder in subject by administering the polypeptides of the invention to said subject.
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: August 22, 2017
    Assignee: Biogen MA Inc.
    Inventors: Frederick R. Taylor, Justin A. Caravella, Alexey A. Lugovskoy, Amna Saeed-Kothe, Ellen A. Garber
  • BINDING PROTEINS, INCLUDING ANTIBODIES, ANTIBODY DERIVATIVES AND ANTIBODY FRAGMENTS, THAT SPECIFICALLY BIND CD154 AND USES THEREOF
    Publication number: 20160200823
    Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.
    Type: Application
    Filed: March 29, 2016
    Publication date: July 14, 2016
    Inventors: LINDA C. BURKLY, JANINE L. FERRANT-ORGETTAS, ELLEN A. GARBER, YEN-MING HSU, LIHE SU, FREDERICK R. TAYLOR, RALPH ADAMS, DEREK THOMAS BROWN, ANDREW GEORGE POPPLEWELL, MARTYN KIM ROBINSON, ANTHONY SHOCK, KERRY LOUISE TYSON
  • Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof
    Patent number: 9321840
    Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: April 26, 2016
    Assignees: UCB BIOPHARMA SPRL, BIOGEN MA INC.
    Inventors: Linda C. Burkly, Janine L. Ferrant-Orgettas, Ellen A. Garber, Yen-Ming Hsu, Lihe Su, Frederick R. Taylor, Ralph Adams, Derek Thomas Brown, Andrew George Popplewell, Martyn Kim Robinson, Anthony Shock, Kerry Louise Tyson
  • Anti-Blood Dendritic Cell Antigen 2 Antibodies And Uses Thereof
    Publication number: 20150299325
    Abstract: Antibodies and antibody fragments that bind to BDCA2 are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to induce death of a plasmacytoid dendritic cell, inhibit production or secretion of inflammatory cytokines and chemokines, and treat or prevent immunological disorders such as inflammatory and autoimmune conditions.
    Type: Application
    Filed: December 10, 2013
    Publication date: October 22, 2015
    Inventors: Justin A. CARAVELLA, Ellen A. GARBER, Dania Mounir RABAH, Frederick R. TAYLOR
  • AGLYCOSYL ANTI-CD154 (CD40 LIGAND) ANTIBODIES AND USES THEREOF
    Publication number: 20150017155
    Abstract: The invention relates to aglycosyl anti-CD154 antibodies or antibody derivatives, characterized by a modification at the conserved N-linked site in the CH2 domains of the Fc portion of said antibody. The invention also relates to the treatment of immune response related diseases and inhibition of unwanted immune responses with such aglycosylated anti-CD154 antibodies or antibody derivatives thereof.
    Type: Application
    Filed: May 16, 2014
    Publication date: January 15, 2015
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Frederick R. Taylor, Christopher D. Benjamin, Linda C. Burkly, Ellen A. Garber
  • HETERODIMERIC FC REGIONS, BINDING MOLECULES COMPRISING SAME, AND METHODS RELATING THERETO
    Publication number: 20140341906
    Abstract: The present invention features inter alia polypeptides comprising heterodimeric Fc regions. In addition, the instant invention provides methods for treating or preventing a disease or disorder in subject by administering the polypeptides of the invention to said subject.
    Type: Application
    Filed: July 13, 2012
    Publication date: November 20, 2014
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Frederick R. Taylor, Justin A. Caravella, Alexey A. Lugovskoy, Amna Saeed-Kothe, Ellen A. Garber
  • BINDING PROTEINS, INCLUDING ANTIBODIES, ANTIBODY DERIVATIVES AND ANTIBODY FRAGMENTS, THAT SPECIFICALLY BIND CD154 AND USES THEREOF
    Publication number: 20140302016
    Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.
    Type: Application
    Filed: June 19, 2014
    Publication date: October 9, 2014
    Inventors: LINDA C. BURKLY, JANINE L. FERRANT-ORGETTAS, ELLEN A. GARBER, YEN-MING HSU, LIHE SU, FREDERICK R. TAYLOR, RALPH ADAMS, DEREK THOMAS BROWN, ANDREW GEORGE POPPLEWELL, MARTYN KIM ROBINSON, ANTHONY SHOCK, KERRY LOUISE TYSON
  • Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof
    Patent number: 8784823
    Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.
    Type: Grant
    Filed: October 22, 2012
    Date of Patent: July 22, 2014
    Assignees: Biogen Idec MA Inc., UCB Biopharma SPRL
    Inventors: Linda C. Burkly, Janine L. Ferrant-Orgettas, Ellen A. Garber, Yen-Ming Hsu, Lihe Su, Frederick R. Taylor, Ralph Adams, Derek Thomas Brown, Andrew George Popplewell, Martyn Kim Robinson, Anthony Shock, Kerry Louise Tyson
  • ANTI-VLA-4 ANTIBODIES
    Publication number: 20140161794
    Abstract: This invention relates to alpha-4 binding antibodies, and fragments thereof.
    Type: Application
    Filed: April 15, 2011
    Publication date: June 12, 2014
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Alexey Lugovskoy, Frederick R. Taylor, Karen Retta McLachlan